Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS'(Centers for Medicare and Medicaid Services) lumbar artificial disc replacement decision prolongs pain for US industry

This article was originally published in Clinica

Executive Summary

The US Centers for Medicare and Medicaid Services' (CMS) denial last week of national coverage for Synthes' lumbar artificial disc replacement, ProDisc-L, will likely have more impact on prospective private usage than for the ostensible CMS target patient group - the over 60s.

You may also be interested in...



COVID Mutants: Vaccine Changes Likely To Need Immunogenicity Studies, Not Big Efficacy Trials

US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. But how to know what variants need a limited study and which one need a big one will be an ongoing challenge, NIH's Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.

PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News

Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.

Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders

New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel